About IGGENIX, INC.
IgGenix, Inc. is a clinical-stage antibody discovery and development company focused on solving allergies and other immunological diseases through innovative biotechnology. The company uses its proprietary SEQ SIFTER™ platform to develop allergen-specific IgG antibodies that block the allergic cascade.
Antibody discovery and developmentSingle cell RNA-sequencing-based discovery platform (SEQ SIFTER™)Development of allergen-specific IgG antibodiesConducting clinical trials for food and environmental allergiesResearch in immunodominant epitopes and allergen-specific therapeutics
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| FEL D 1-SPECIFIC HUMAN IGE CLASS SWITCHED TO IGE MONOCLONAL ANTIBODIES | Department of Health and Human Services | $100K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to IGGENIX, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.